A detailed history of Brown Brothers Harriman & CO transactions in Organon & Co. stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 4,130 shares of OGN stock, worth $61,495. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,130
Previous 4,472 7.65%
Holding current value
$61,495
Previous $92,000 14.13%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$18.65 - $23.03 $6,378 - $7,876
-342 Reduced 7.65%
4,130 $79,000
Q2 2024

Aug 09, 2024

BUY
$17.45 - $21.96 $7,555 - $9,508
433 Added 10.72%
4,472 $92,000
Q1 2024

May 10, 2024

SELL
$13.78 - $18.8 $2,218 - $3,026
-161 Reduced 3.83%
4,039 $75,000
Q4 2023

Feb 12, 2024

SELL
$10.95 - $17.32 $69,116 - $109,323
-6,312 Reduced 60.05%
4,200 $60,000
Q3 2023

Nov 13, 2023

SELL
$16.59 - $23.77 $4,329 - $6,203
-261 Reduced 2.42%
10,512 $182,000
Q2 2023

Aug 07, 2023

SELL
$19.27 - $24.63 $6,416 - $8,201
-333 Reduced 3.0%
10,773 $224,000
Q1 2023

May 11, 2023

SELL
$21.42 - $32.08 $5,183 - $7,763
-242 Reduced 2.13%
11,106 $261,000
Q4 2022

Feb 09, 2023

SELL
$23.31 - $28.61 $39,323 - $48,265
-1,687 Reduced 12.94%
11,348 $317,000
Q3 2022

Nov 10, 2022

SELL
$23.4 - $34.25 $247,033 - $361,577
-10,557 Reduced 44.75%
13,035 $305,000
Q2 2022

Aug 11, 2022

SELL
$31.66 - $38.9 $50,371 - $61,889
-1,591 Reduced 6.32%
23,592 $796,000
Q1 2022

May 13, 2022

SELL
$30.45 - $39.36 $23,751 - $30,700
-780 Reduced 3.0%
25,183 $880,000
Q4 2021

Feb 14, 2022

SELL
$28.67 - $37.13 $105,906 - $137,158
-3,694 Reduced 12.46%
25,963 $791,000
Q3 2021

Nov 15, 2021

SELL
$28.63 - $35.64 $123,223 - $153,394
-4,304 Reduced 12.67%
29,657 $972,000
Q2 2021

Aug 13, 2021

BUY
$28.45 - $38.0 $966,190 - $1.29 Million
33,961 New
33,961 $1.03 Million

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $3.79B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Brown Brothers Harriman & CO Portfolio

Follow Brown Brothers Harriman & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.